GLP-1 Medications and Endometriosis: What the Research Shows

*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. This article is for educational and informational purposes only and does not constitute medical advice. Clinical research cited here was conducted using FDA-approved pharmaceutical formulations unless otherwise noted. If you have endometriosis or another gynecological condition, consult your OB-GYN, gynecologist, or prescribing physician before starting, stopping, or adjusting any medication. Individual results vary. All prescribing at Prescriva is performed by independently licensed healthcare providers.*

---

For many women, endometriosis is a condition that reshapes daily life. The chronic pelvic pain, the unpredictable flares, the years it often takes to receive a proper diagnosis. And for those also managing weight, the picture is more complicated still: the same inflammatory pathways that drive endometriosis lesion growth appear to intersect, in ways researchers are only beginning to map, with the metabolic systems that GLP-1 medications target.

This is not a topic with simple answers yet. GLP-1 receptor agonists like semaglutide and tirzepatide were developed for blood sugar control and weight management, not for endometriosis. But as scientists have studied these medications more closely, they have noticed something worth paying attention to: GLP-1 has measurable effects on the inflammatory and immune pathways that are central to how endometriosis behaves.

Here is what the current evidence shows, where the research is heading, and what it does not yet prove.

What Endometriosis Is and Why Inflammation Matters

Endometriosis is a chronic condition in which tissue similar to the uterine lining grows outside the uterus, typically on the ovaries, fallopian tubes, and surrounding pelvic structures. It affects an estimated 190 million women and girls worldwide across reproductive years and is among the most common causes of chronic pelvic pain and infertility.

The condition is driven by inflammation. Endometriosis lesions create and sustain a local inflammatory environment, recruiting immune cells called macrophages and producing elevated levels of inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and prostaglandins. A 2026 review in *Medicina* (Ghilea Seles L et al., PMID: [42195138](https://pubmed.ncbi.nlm.nih.gov/42195138/)) examined how chronic inflammation in endometriosis drives reproductive dysfunction, noting that the macrophage-dominant peritoneal inflammatory environment is both a consequence of endometriosis lesions and a driver of their persistence and growth.

A 2025 review in *Frontiers in Immunology* (Shifon S et al., PMID: [41488658](https://pubmed.ncbi.nlm.nih.gov/41488658/)) characterized endometriosis as fundamentally an immune-mediated disease. The peritoneal fluid of women with endometriosis contains elevated populations of inflammatory macrophages that are phenotypically distinct from those found in healthy controls, with altered cytokine secretion profiles that promote lesion survival and angiogenesis.

This immune and inflammatory character of endometriosis is relevant to any conversation about GLP-1 medications, because those medications have documented effects on these same immune pathways.

A Significant Research Finding: GLP-1 Is Reduced in Endometriosis

One of the most intriguing findings in the intersection of GLP-1 biology and endometriosis came from a 2022 study published in the *International Journal of Molecular Sciences* (Krasnyi A et al., PMID: [36142272](https://pubmed.ncbi.nlm.nih.gov/36142272/)).

The researchers analyzed peritoneal fluid from women with endometriosis and compared it to fluid from healthy controls. Among the metabolic markers measured, GLP-1 levels were significantly lower in the peritoneal fluid of endometriosis patients. The same study also found reductions in ghrelin, glucagon, and visfatin in the endometriosis group.

The implications of this finding are not yet fully understood. Peritoneal GLP-1 is thought to be produced locally by immune cells and intestinal L-cells that communicate with the peritoneal cavity. The finding raises the possibility that the peritoneal inflammatory environment in endometriosis actively depletes or suppresses local GLP-1 signaling, or alternatively, that reduced GLP-1 activity may contribute to the maintenance of that inflammatory environment.

This is an area where more research is clearly needed. But it establishes that GLP-1 signaling is not simply unrelated to endometriosis biology. There is a measurable difference in GLP-1 levels in the very tissue space where endometriosis lesions live.

How GLP-1 Medications Reduce Inflammation: Mechanisms Relevant to Endometriosis

GLP-1 receptor agonists like semaglutide and tirzepatide have well-documented anti-inflammatory effects that operate through several distinct pathways. These mechanisms are relevant when thinking about endometriosis because endometriosis is fundamentally an inflammatory disease.

Macrophage modulation. A 2019 study in the *International Journal of Immunopharmacology* (Lu J et al., PMID: [31685436](https://pubmed.ncbi.nlm.nih.gov/31685436/)) demonstrated that the GLP-1 receptor agonist exendin-4 significantly reduced inflammatory signaling in activated macrophages, suppressing the production of TNF-alpha, IL-6, and other pro-inflammatory cytokines. Since macrophages are the primary inflammatory driver in endometriosis peritoneal fluid, this mechanism is directly relevant to the disease biology, even though the study was not conducted in endometriosis tissue specifically.

cAMP-mediated anti-inflammatory pathways. A 2024 analysis in *Inflammation Research* (Stoicovy R et al., PMID: [39305297](https://pubmed.ncbi.nlm.nih.gov/39305297/)) confirmed that GLP-1 receptor activation modulates inflammation through cyclic AMP (cAMP) signaling, which inhibits NF-kB, a master regulator of inflammatory gene expression. NF-kB is overactive in endometriosis lesions and contributes to the sustained production of inflammatory mediators that drive lesion survival.

Weight loss as an indirect anti-inflammatory pathway. When GLP-1 medications produce significant weight loss, adipose tissue, which is metabolically active and produces pro-inflammatory adipokines like leptin, decreases. This leads to systemic reductions in circulating inflammatory markers. For women with endometriosis who also carry excess weight, this indirect pathway may contribute meaningfully to reducing systemic inflammatory burden, even if direct lesion reduction has not been studied.

Endometriosis, Weight, and the Metabolic Connection

The relationship between body weight and endometriosis is more nuanced than with most conditions. Research has shown that endometriosis patients, on average, tend to have lower BMI than women without the condition, which complicates any simple narrative about weight and disease severity. However, the picture shifts when you look at specific subpopulations.

A 2026 review in *Cureus* (Desai H et al., PMID: [41798441](https://pubmed.ncbi.nlm.nih.gov/41798441/)) examined the state of evidence on endometriosis and obesity, finding that while classic endometriosis presentations skew toward lower BMI, women with obesity and endometriosis face amplified inflammatory burden. Adipose-derived inflammatory cytokines, particularly leptin and TNF-alpha, appear to promote endometriosis lesion growth and pain severity, and obesity-associated insulin resistance may impair the immune clearance of ectopic endometrial tissue.

For women with endometriosis who are also managing overweight or obesity, the metabolic effects of GLP-1 medications may address several overlapping concerns simultaneously: reducing systemic inflammation through weight loss, improving insulin sensitivity, and potentially reducing the adipose-tissue-derived cytokine milieu that feeds lesion activity.

A 2025 narrative review in *Reproductive Biology and Endocrinology* (Duah M and Seifer DB, PMID: [39762910](https://pubmed.ncbi.nlm.nih.gov/39762910/)) addressed medical therapy for obesity in women of reproductive age specifically, noting that GLP-1 receptor agonists represent the most effective pharmacological option in this population when lifestyle interventions are insufficient. The authors noted that for women with conditions like polycystic ovary syndrome and endometriosis, where metabolic dysfunction and inflammation intersect with reproductive health, weight management carries particular clinical importance.

The Chronic Pain Dimension

Endometriosis is one of the most common causes of chronic pelvic pain, and chronic pain has its own inflammatory biology. A 2025 review in *Cureus* (McMasters R and Mora C, PMID: [41257114](https://pubmed.ncbi.nlm.nih.gov/41257114/)) examined meta-inflammation, the low-grade systemic inflammatory state that underlies many chronic pain conditions, and proposed that interventions targeting systemic inflammation may have value in reducing chronic pain burden beyond the primary disease process.

GLP-1 medications, with their documented effects on systemic inflammatory markers like C-reactive protein and IL-6, could theoretically contribute to this broader anti-inflammatory effect in women managing endometriosis-related chronic pain alongside excess weight. This remains speculative, and clinical trials specifically in endometriosis patients have not yet been conducted. But the mechanistic basis for inquiry exists.

What This Research Does Not Yet Prove

It is important to be precise about the limits of current evidence.

No clinical trials have tested GLP-1 receptor agonists specifically in women with endometriosis to measure effects on lesion burden, pain scores, or disease progression. The Krasnyi 2022 finding about reduced peritoneal GLP-1 levels is a signal, not a treatment blueprint. The macrophage-modulating and anti-inflammatory mechanisms documented in other contexts have not been specifically replicated in endometriosis tissue or endometriosis patient populations.

GLP-1 medications are also not indicated for endometriosis and should not be sought as a treatment for this condition based on current evidence. Their approved uses are for weight management and type 2 diabetes, and prescribing at Prescriva is based on your individual medical evaluation and weight management goals, not endometriosis management.

Any woman with endometriosis who is considering a GLP-1 medication for weight management should discuss the full picture with her gynecologist and, if applicable, the provider who manages her endometriosis treatment.

What to Ask Your Provider

If you have endometriosis and are exploring weight management options including GLP-1 medications, here are questions worth raising with your healthcare team:

• Given my endometriosis, what other conditions or medications should my provider be aware of before considering a GLP-1 medication?
• Are there any known interactions between GLP-1 medications and the hormonal therapies commonly used for endometriosis management, such as hormonal contraceptives, progestins, or GnRH agonists?
• If I do pursue a GLP-1 program, how should my care be coordinated between my weight management provider and my gynecologist?
• Are there monitoring considerations specific to my situation?

The Bottom Line

The intersection of GLP-1 biology and endometriosis is a genuinely emerging area of research. The finding that GLP-1 levels are reduced in the peritoneal fluid of endometriosis patients, combined with the well-documented anti-inflammatory mechanisms of GLP-1 receptor agonists, raises questions that deserve further scientific investigation.

For women with endometriosis who are also managing overweight or obesity, GLP-1 medications represent a legitimate and evidence-based option for weight management under licensed medical supervision. Whether those medications offer any direct benefit to endometriosis-specific outcomes is a question that current research cannot yet answer.

What is clear is that weight, inflammation, and hormonal health are deeply interconnected for women with endometriosis, and that managing excess weight through a medically supervised program addresses at least some of those connections in ways that are supported by evidence.

---

Frequently Asked Questions

Can semaglutide or tirzepatide be prescribed for endometriosis?

No. GLP-1 receptor agonists are not approved or indicated for endometriosis treatment. They may be prescribed for weight management by a licensed provider, which is a separate clinical indication. Any use in the context of endometriosis would be entirely off-label and would require careful coordination with your gynecologist.

Is it safe to take a GLP-1 medication if I am on hormonal therapy for endometriosis?

This is a question your prescribing provider and gynecologist need to answer together based on your specific medications, doses, and health history. GLP-1 medications do slow gastric motility, which can theoretically affect the absorption of oral medications. Your full medication list should be reviewed.

Does losing weight help endometriosis symptoms?

Some evidence suggests that in women with endometriosis and obesity, reducing excess adipose tissue may reduce the pro-inflammatory adipokine levels that appear to promote lesion activity and pain. However, endometriosis is a complex condition and weight loss is not a cure or a reliable treatment. Individual responses vary considerably.

Are GLP-1 medications safe during pregnancy for someone with endometriosis?

GLP-1 receptor agonists are not recommended during pregnancy. Women of reproductive age who are considering a GLP-1 program should discuss contraception and family planning with their provider. Endometriosis is a known factor in reduced fertility, which adds additional complexity to these conversations.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus). Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Mounjaro or Zepbound).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Prescriva LLC, doing business as Prescriva, is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.